Pancreatic Cancer Research

Clinical trialPhase 2Enrolling by invitation

Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

A Phase II Study of Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel as a First-line Treatment for Subjects With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Outcome
Ongoing
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Start
1 July 2023
Listed end
September 2026
Enrollment
30 participants
Sites
1
Primary outcomes
Progression-free survival time
Sponsor type
Academic / other
Results posted
No
Last update
13 July 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to determine the efficacy of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.

Detailed description public domain (ClinicalTrials.gov)

This is a single-institution, prospective, open, one-armed phase Ⅱ clinical trial of sitagliptin combined with gemcitabine and nab-paclitaxel.